Promoted Companies
SORT BY:
DARA Biosciences, Inc. (DARA)
| Total paid for Promotions this month: | $0 | ||
| E-mails this Month: | 2 | ||
| Estimated Volume Generated: | $0 | ||
| Research Report on DARA: | Click to see | ||
| * The information presented is based on information for Jun , 2014 | |||
Its Experimental Compound Gets FDA Orphan Drug Designation for... Jun 16, 2014 08:11
Its Experimental Compound Gets FDA Orphan Drug Designation for Treatment of Multiple Myeloma
(Mailing list information, including unsubscription instructions, is located at the end of this message.)
DARA BioSciences, Inc. (DARA)
Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
Multiple myeloma is the second most common
...read more
| Promoter: | penny to buck | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | Unknown compensation | UNKNOWN |
| Max Profit: 13.43 % | Gain at close: -4.48 % |
Its Experimental Compound Gets FDA Orphan Drug Designation for... Jun 16, 2014 07:44
Its Experimental Compound Gets FDA Orphan Drug Designation for Treatment of Multiple Myeloma
(Mailing list information, including unsubscription instructions, is located at the end of this message.)
DARA BioSciences, Inc. (DARA)
Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
Multiple myeloma is the second most common
...read more
| Promoter: | Double in stocks | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | Unknown compensation | UNKNOWN |
| Max Profit: 13.43 % | Gain at close: -4.48 % |
DARA, MKTG, SLXP, - PennyToBuck.com Watch List For Wednesday Nov.... Nov 08, 2011 19:52
SLXP, Salix Pharmaceuticals, Ltd.
** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.
SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.
SLXP develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal
...read more
| Promoter: | penny to buck | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | Unknown compensation | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: -22.29 % |
SLXP, MKTG, DARA, - CRWESelect.com Stocks To Watch For Wednesday... Nov 08, 2011 19:51
SLXP, Salix Pharmaceuticals, Ltd.
** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.
SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.
SLXP develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal
...read more
| Promoter: | Crweselect.com | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | Unknown compensation | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: -22.29 % |
SLXP, DARA, MKTG, - DoubleInStocks.com Stock Watch For Wednesday... Nov 08, 2011 19:50
SLXP, Salix Pharmaceuticals, Ltd.
** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.
SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.
SLXP develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal
...read more
| Promoter: | Double in stocks | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | Unknown compensation | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: -22.29 % |
SLXP, MKTG, DARA, - Stock-PR.com Stock Watch For Wednesday Nov.... Nov 08, 2011 19:50
SLXP, Salix Pharmaceuticals, Ltd.
** On its third quarter fiscal 2011 results, SLXP posted total product revenue of $146.2 million, an 81% increase year over year.
SLXP is increasing its estimate of 2011 total product revenue to approximately $535 million, which represents 59% growth over 2010 revenue.
SLXP develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal
...read more
| Promoter: | Stock-pr | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | Unknown compensation | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: -22.29 % |
PennyOmega.com Stocks In Action on Tuesday! Nov 01, 2011 12:43
ICLK, interCLICK, Inc.
** Yahoo! Inc. reported a definitive agreement to acquire ICLK.
Under the terms of the agreement, Yahoo! will commence an all cash tender offer for all outstanding shares of common stock of ICLK at $9.00 per share. The transaction has an estimated total equity value of approximately $270 million.
Powered by OSM, ICLK offers proprietary data-valuation capabilities combining analytical expertise
...read more
| Promoter: | pennyomega.com | Paying Party: | No Third Party |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | No compensation | UNKNOWN |
| Max Profit: 0.59 % | Gain at close: -1.76 % |
PennyToBuck.com Stocks In Action on Tuesday! Nov 01, 2011 12:33
ICLK, interCLICK, Inc.
** Yahoo! Inc. reported a definitive agreement to acquire ICLK.
Under the terms of the agreement, Yahoo! will commence an all cash tender offer for all outstanding shares of common stock of ICLK at $9.00 per share. The transaction has an estimated total equity value of approximately $270 million.
Powered by OSM, ICLK offers proprietary data-valuation capabilities combining analytical
...read more
| Promoter: | penny to buck | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | Unknown compensation | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: -22.29 % |
Stock-PR.com Stocks In Action on Tuesday! Nov 01, 2011 12:31
ICLK, interCLICK, Inc.
** Yahoo! Inc. reported a definitive agreement to acquire ICLK.
Under the terms of the agreement, Yahoo! will commence an all cash tender offer for all outstanding shares of common stock of ICLK at $9.00 per share. The transaction has an estimated total equity value of approximately $270 million.
Powered by OSM, ICLK offers proprietary data-valuation capabilities combining analytical expertise
...read more
| Promoter: | Stock-pr | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | Unknown compensation | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: -22.29 % |
CRWESelect.com Stocks In Action on Tuesday! Nov 01, 2011 12:31
ICLK, interCLICK, Inc.
** Yahoo! Inc. reported a definitive agreement to acquire ICLK.
Under the terms of the agreement, Yahoo! will commence an all cash tender offer for all outstanding shares of common stock of ICLK at $9.00 per share. The transaction has an estimated total equity value of approximately $270 million.
Powered by OSM, ICLK offers proprietary data-valuation capabilities combining analytical
...read more
| Promoter: | Crweselect.com | Paying Party: | UNKNOWN |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| DARA | Unknown compensation | UNKNOWN |
| Max Profit: 0.00 % | Gain at close: -22.29 % |